Skip to main content
. 2021 Apr 18;13(8):1949. doi: 10.3390/cancers13081949

Figure 1.

Figure 1

Interaction of main immune co-stimulatory/co-inhibitory molecules and their corresponding receptors. Cancer cells and other cells in the tumor microenvironment express a variety of inhibitory and stimulatory ligands that bind to their cognate receptors on immune cells, thereby leading to immune-modulation. These ligand-receptor pairs are known as immune checkpoints. Tregs = regulatory T cells; MDSC = myeloid-derived suppressor cell; APC = antigen presenting cell; TCR = T-cell receptor.